Hormonal Birth Control & Heart Risk: Impact of Stress & PTSD in Women
- New research is shedding light on the complex interplay between hormonal contraception, stress and cardiovascular health in women.
- Cardiovascular disease (CVD) remains the leading cause of death for women in the United States, claiming over 400,000 lives annually.
- Historically, research on hormonal contraceptives has largely centered on young, relatively healthy women.
New research is shedding light on the complex interplay between hormonal contraception, stress and cardiovascular health in women. A study published in JAMA Network Open on , explores how the use of hormonal contraceptives may influence cardiovascular and thrombotic risk, particularly in women experiencing stress-related psychiatric conditions like anxiety, depression, or post-traumatic stress disorder (PTSD).
Cardiovascular disease (CVD) remains the leading cause of death for women in the United States, claiming over 400,000 lives annually. Recognizing stress as a significant risk factor for CVD, and acknowledging the higher prevalence of stress-related psychiatric disorders among women, researchers are increasingly focused on sex-specific factors contributing to cardiovascular health. Hormonal contraception, used by approximately 9.1 million women in the U.S., is one such factor that warrants further investigation.
Historically, research on hormonal contraceptives has largely centered on young, relatively healthy women. This has left a significant gap in understanding how these contraceptives affect women already coping with the challenges of stress-related psychiatric disorders. “Past research…has focused almost entirely on young, relatively healthy women,” explains Antonia Seligowski, Ph.D., of the Neurocardiac Effects of Stress & Trauma Laboratory at Mass General Brigham, and senior author of the study. “very little is known about how hormonal contraceptives affect women with stress-related psychiatric disorders.” This new study represents a crucial step towards addressing this knowledge deficit.
Examining the Combined Effects
The research team, led by Jordan Thomas, Ph.D., of the University of Kansas, analyzed health care records from a cohort of 31,824 women participating in the Mass General Brigham Biobank. The analysis focused on identifying diagnoses of stress-related disorders, major adverse cardiovascular events (MACE), and deep-vein thrombosis, alongside prescription records for hormonal contraceptives. The central question driving the study was whether hormonal contraceptive use is linked to cardiovascular and thrombotic risk differently in women with and without pre-existing stress-related disorders.
Key Findings: A Nuanced Picture
The findings revealed a nuanced relationship. For the majority of women, including those with a history of anxiety or depression, hormonal contraceptive use was associated with a lower risk of MACE. However, this protective association was not observed in women with PTSD. “Although preliminary, these findings suggest that cardiovascular risk may vary among women who use hormonal contraceptives—especially differing for those with PTSD,” Dr. Seligowski notes.
This suggests that the impact of hormonal contraceptives on cardiovascular health isn’t uniform and may be significantly influenced by a woman’s mental health history. The study highlights the importance of considering individual patient characteristics when evaluating the risks and benefits of hormonal contraception.
Implications for Clinical Practice
While these findings are preliminary and require further validation, they have important implications for clinical practice. If confirmed by future studies, clinicians may need to incorporate a patient’s history of stress-related psychiatric disorders – particularly PTSD – into discussions about hormonal contraceptive options. This individualized approach could help optimize cardiovascular risk management for women using these medications.
Future Research Directions
The research team is planning follow-up studies to further investigate these findings. A planned clinical study will aim to collect new data on the relationship between specific hormonal contraceptive formulations and CVD risk factors in women. This will include assessing blood pressure, vascular endothelial function, and blood-based clotting markers. Crucially, the study will also examine whether these effects differ between women with and without stress-related psychiatric disorders. Participants will be followed over time to track clinical outcomes, such as thrombotic events.
This ongoing research underscores the need for a more comprehensive understanding of the complex interplay between hormonal contraception, mental health, and cardiovascular risk in women. By continuing to explore these relationships, researchers hope to inform clinical guidelines and improve the cardiovascular health of women across diverse populations.
Journal information: JAMA Network Open